Novartis India

What Novartis India does

Novartis India Limited (BSE: 500672) is a publicly listed pharmaceutical company headquartered in Mumbai, India, operating in cardiovascular disease, oncology, and immunology. Its commercial portfolio includes Pluvicto (lutetium 177Lu vipivotide tetraxetan, India's first regulatory authority-approved radioligand therapy for PSMA-positive metastatic prostate cancer), Voveran (pain management), Inclisiran (RNA-based cholesterol management), and Coartem Baby (anti-malaria). Distribution is executed through traditional pharmaceutical channels for established products and through select hospitals and nuclear medicine centers for advanced therapies like Pluvicto.

India serves as one of three global Novartis development hubs alongside Basel and the US, with the Novartis Corporate Centre Hyderabad (NOCC) housing over 350 scientists and advanced platforms in radioligand therapy, xRNA, and cell and gene therapies. A Phase I clinical research facility has been initiated in Ahmedabad. The workforce exceeds 9,000 employees, and the India operations contribute to nearly every molecule Novartis commercializes globally.

In February 2026, Novartis AG divested its entire 70.68% controlling stake to a ChrysCapital-led consortium (WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners) for approximately ₹1,446 crore ($159 million), valuing the listed entity at ~₹2,050 crore. Novartis AG retained its wholly-owned unlisted subsidiary Novartis Healthcare Private Limited, which operates the commercial arm, Hyderabad corporate center, and R&D clinical trial teams. Following the change of control, the listed entity must remove all Novartis branding from its name within 120 days. FY2026 revenue was ₹354.33 crore (marginally down 0.54%), with full-year net profit of ₹93.18 crore (down 7.65%), although Q4 FY2026 sales rose 7.95% year-over-year.

Name

Novartis India

Legal name

Novartis India Limited

Website

https://novartis.in

Company type

Public

Founded year

1947

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Novartis India Limited is a publicly listed pharmaceutical company selling innovative medicines in cardiovascular, oncology, and immunology, including India's first approved radioligand therapy Pluvicto for prostate cancer, distributed through hospitals and traditional pharma channels.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Innovative pharmaceuticals
• Oncology therapeutics
• Cardiovascular medicines
• Radioligand therapy
• Prescription drug distribution

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue from selling innovative medicines including prescription drugs for cardiovascular disease, oncology, immunology, and pain management. Products include Voveran, Coartem Baby, Inclisiran, and Pluvicto.
2. Advanced Therapy Distribution: Distribution of specialized radioligand therapies through hospital and nuclear medicine center partnerships, targeting metastatic prostate cancer patients

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Novartis India develops, manufactures, and distributes branded innovative pharmaceutical medicines in three therapeutic areas: cardiovascular disease, oncology, and immunology. Its commercial portfolio includes Pluvicto (a radioligand therapy for PSMA-positive prostate cancer), Inclisiran (an RNA-based cholesterol management therapy), Voveran (a pain management medicine), and Coartem Baby (an anti-malaria treatment). The company also serves as one of three global development hubs for the Novartis group, conducting drug development, Phase I clinical research, and advanced platform work in radioligand therapy, xRNA, and cell and gene therapies.

Product overview

Novartis India operates as an innovative medicines company focused on three therapeutic areas: cardiovascular disease, oncology, and immunology. The company offers a portfolio of branded pharmaceutical products including Pluvicto (a radioligand therapy for prostate cancer), Inclisiran (a cardiovascular drug), and Voveran (a pain management medicine). India serves as one of Novartis's three global development hubs alongside Basel and the US, with advanced therapeutic platforms including radioligand therapy, xRNA, and cell and gene therapies. Products are made available through select hospitals, nuclear medicine centres, and healthcare institutions across India.

Differentiator

Problem solved

Functional benefit

Products and services

• Pluvicto (lutetium 177Lu vipivotide tetraxetan) India's first regulatory authority-approved radioligand therapy for PSMA-positive metastatic prostate cancer, using lutetium-177 to precisely target prostate cancer cells while minimizing exposure to healthy tissues. Distributed to select hospitals and nuclear medicine centers for treatment of eligible patients.
• Inclisiran Cardiovascular drug using RNA-based technology for cholesterol management, part of Novartis India's cardiovascular portfolio and contributing to its innovative medicines offering for chronic disease management.
• Voveran Pain management medicine sold through Novartis India's commercial operations via traditional pharmaceutical distribution networks, targeting healthcare professionals and patients requiring pain management therapy.
• Coartem Baby Anti-malaria treatment medication included in Novartis's global portfolio, with India contributing to its development. Marketed by Novartis India as part of its infectious disease and global health therapeutic portfolio.

Quantifiable outcome

• 769 million lives touched by Novartis products globally
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Select Hospitals and Nuclear Medicine CenterscoreChannel Partner/ Reseller/ Distributor · 16 June 2026Partnership with healthcare institutions and oncologists to make Pluvicto available through select hospitals and nuclear medicine centers across India. Supports treatment readiness and expanded access to radioligand therapies.
• Novartis Healthcare Private LimitedcoreOthersNovartis AG retained its wholly-owned subsidiary Novartis Healthcare Private Limited, which operates the commercial arm, corporate center in Hyderabad, and R&D clinical trial teams, separate from the divested listed entity.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Zydus Lifesciences: Indian pharmaceutical major with branded formulations and biosimilars across multiple therapeutic areas including oncology and cardiovascular. Operates with similar GTM motion targeting healthcare professionals in India.
• Glenmark Pharmaceuticals: Indian pharma company with branded generics and specialty products across cardiovascular, respiratory, and oncology. Direct competitor to Novartis India in the Indian branded pharma market with similar customer segments.
• Dr. Reddy's Laboratories: Indian multinational pharma with branded formulations, biosimilars, and specialty products. Comparable to Novartis India in branded pharma distribution model and therapeutic area focus across cardiovascular and oncology.
• Cipla: Major Indian pharmaceutical company with strong branded generics portfolio across respiratory, cardiovascular, and oncology. Directly comparable to Novartis India in operating model (sales-led to healthcare professionals) and product mix in the Indian market.
• Lupin: Leading Indian pharma company with branded and generic portfolio spanning cardiovascular, oncology, and specialty therapies. Direct competitor in the Indian branded pharmaceutical market with similar enterprise field sales GTM.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue, offering branded formulations, generics, and specialty products across cardiovascular, oncology, and immunology - the same therapeutic areas Novartis India targets. Comparable in scale, GTM motion, and product breadth within the Indian pharma market.

Emerging players

• Biocon: Indian biopharmaceutical company focused on biologics, biosimilars, and novel biologics including oncology. Comparable to Novartis India's biologics and cell/gene therapy platforms, though more focused on biosimilars than radioligand therapy.

Broad incumbents

• AstraZeneca Pharma India: Indian subsidiary of global biopharmaceutical major AstraZeneca, focused on oncology, cardiovascular, and respiratory therapies. Comparable as a multinational pharma India subsidiary with branded innovative medicines - the same model Novartis India operated under before PE acquisition.
• Pfizer India: Indian subsidiary of global pharma major Pfizer, offering branded innovative medicines across therapeutic areas. Directly comparable as a multinational pharma India entity with similar GTM, product mix, and target customer segments to Novartis India.
• Bayer Pharmaceuticals India: Indian arm of global pharma major Bayer, offering branded innovative medicines in cardiovascular, oncology, and women's health. Comparable multinational pharma India model with focus on innovative therapies rather than generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/novartisindia

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis India